Clinical reference Biomarker Directory
Back to directory

SELP

Emerging

P-selectin drives the abnormal blood cell adhesion behind sickle cell vaso-occlusive crises, now a specific drug target (crizanlizumab).

Also known as P-selectin CD62P
In plain language

P-selectin makes blood cells abnormally sticky, which is part of what causes painful blood vessel blockages in sickle cell disease. A drug that blocks this exact molecule was approved specifically to reduce how often these painful episodes happen.

Biomarker & context

P-selectin (SELP) is a cell-adhesion molecule expressed on activated platelets and endothelial cells, promoting the abnormal blood cell adhesion that drives vaso-occlusive pain crises in sickle cell disease.

What it indicates

Elevated P-selectin reflects the endothelial and platelet activation underlying sickle cell vaso-occlusive events, connecting directly to the sickle cell disease discussion much earlier in this biomarker set.

Diagnosis & clinical testing

P-selectin isn't typically measured as a standalone diagnostic blood test in routine sickle cell management; rather, it's the molecular rationale and drug target underlying a specific therapeutic approach.

Guiding treatment

Crizanlizumab, an anti-P-selectin antibody, was FDA-approved in 2019 specifically to reduce pain crisis frequency in sickle cell disease — one of several newer sickle cell therapies (alongside the voxelotor withdrawal and hydroxyurea updates discussed earlier) that have reshaped treatment in just the past few years.

Clinical significance

One of several newer sickle cell therapies that have reshaped treatment in recent years, alongside voxelotor and hydroxyurea updates.

References
  1. FDA. (2019). Crizanlizumab (Adakveo) Approval for Sickle Cell Disease.